Emcure's semaglutide gets CDSCO nod for fatty liver disease MASH
India's first GLP-1 receptor agonist cleared for non-cirrhotic MASH with moderate to advanced fibrosis. Poviztra adds a major new indication to its existing approvals for weight management, CVD, and adolescent obesity.
What's new
- CDSCO approved Emcure's Poviztra for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis.
- First GLP-1 receptor agonist cleared in India for this progressive liver condition.
- Approval backed by Phase III ESSENCE trial: 63% resolved steatohepatitis, 37% improved fibrosis.
Why this matters
MASH, closely linked to obesity and diabetes, is a growing unmet need. Emcure, with its existing gastroenterology network via Juventus Healthcare, is now the only mid-cap pharma in India offering a proven GLP-1 therapy for this indication, facing limited competition and a large addressable patient pool.
What we're watching
- How fast Emcure expands diagnosis and awareness campaigns through its gastro network.
- Pricing strategy for Poviztra in MASH vs existing weight-loss indications.
- Competitive response from other GLP-1 players entering the Indian market.
The full read
Emcure Pharmaceuticals has secured CDSCO approval for Poviztra (semaglutide) to treat non-cirrhotic MASH in adults with moderate to advanced liver fibrosis. That makes it the first GLP-1 receptor agonist cleared in India for this progressive liver disease—a condition closely tied to obesity and diabetes, both booming in the country. The nod rests on the Phase III ESSENCE trial, where 63% of patients resolved steatohepatitis and 37% saw fibrosis improvement. For Emcure (market cap ₹35,664 cr), the expanded label is a material lift. It already sells Poviztra for weight management, CVD, and adolescent obesity. The MASH indication lets it tap into a large, underserved pool using its existing gastroenterology network via Juventus Healthcare. With limited competition in India for a GLP-1 in this space, the approval strengthens Emcure's specialty portfolio and growth outlook.
Questions answered
- What is MASH and how common is it in India?
- Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of fatty liver disease. It affects a significant portion of the obese and diabetic population in India, though exact prevalence data is lacking. The approval targets adults with moderate to advanced fibrosis.
- What evidence supported this approval?
- The global Phase III ESSENCE trial demonstrated that semaglutide resolved steatohepatitis in 63% of patients and improved liver fibrosis in 37%, both statistically significant outcomes.
- How does Emcure plan to commercialise this new indication?
- Emcure will leverage its existing gastroenterology network through subsidiary Juventus Healthcare to improve MASH awareness, diagnosis, and treatment access, working closely with healthcare professionals.
- What other indications does Poviztra have in India?
- Poviztra is already approved for chronic weight management, cardiovascular disease risk reduction, and adolescent obesity. The MASH approval adds a fourth indication.